In Every Issue
HealthTech
Astellas and Welldoc Pair Up for Digital Therapeutics Trend Watch: [...]
By PharmaVOICE Staff
Artificial Intelligence
Cyclica and ATAI Partner to Develop Drugs to Treat Mental [...]
By PharmaVOICE Staff
Innovator’s Corner
Fish Skin for Wounds Fertram Sigurjonsson, Founder and CEO of [...]
By Fertram Sigurjonsson, Founder and CEO of Kerecis
Last Word
Creating an Innovative Culture Fabrice Chouraqui, former president of Novartis [...]
By Fabrice Chouraqui, former president of Novartis Pharmaceuticals US
HealthTech
Astellas and Welldoc Pair Up for Digital Therapeutics Trend Watch: [...]
Astellas and Welldoc Pair Up for Digital Therapeutics Trend Watch: [...]
By
PharmaVOICE Staff
Artificial Intelligence
Cyclica and ATAI Partner to Develop Drugs to Treat Mental [...]
Cyclica and ATAI Partner to Develop Drugs to Treat Mental [...]
By
PharmaVOICE Staff
Innovator’s Corner
Fish Skin for Wounds Fertram Sigurjonsson, Founder and CEO of [...]
Fish Skin for Wounds Fertram Sigurjonsson, Founder and CEO of [...]
By
Fertram Sigurjonsson, Founder and CEO of Kerecis
Last Word
Creating an Innovative Culture Fabrice Chouraqui, former president of Novartis [...]
Creating an Innovative Culture Fabrice Chouraqui, former president of Novartis [...]
By
Fabrice Chouraqui, former president of Novartis Pharmaceuticals US
On The Cover
Small Pharma Driving Big Pharma Innovation
The Path to R&D Innovation Lies in the Power of Small Pharma Visionary thought leaders such as Bernard Munos of InnoThink and the Milken Institute and Paul Stoffels, M.D., vice chairman of the executive committee and chief scientific officer, Johnson & Johnson, have been advocating for years that the blockbuster model is broken and unsustainable. [...]
The Path to R&D Innovation Lies in the Power of Small Pharma Visionary thought leaders such as Bernard Munos of InnoThink and the Milken Institute and Paul Stoffels, M.D., vice chairman of the executive committee and chief scientific officer, Johnson & Johnson, have been advocating for years that the blockbuster model is broken and unsustainable. [...]
By
Robin Robinson
Features
SHOWCASE: High-Science Brands: Making Connections for High Science Brands
The growth of high-science brands has changed the life sciences landscape, and with it the strategies companies need to develop to market their products must also undergo a significant shift. Cancer immunotherapies as well as other high-science brands will account for billion in sales by 2024, according to GlobalData. Furthermore, it’s been estimated that [...]
The growth of high-science brands has changed the life sciences landscape, and with it the strategies companies need to develop to market their products must also undergo a significant shift. Cancer immunotherapies as well as other high-science brands will account for billion in sales by 2024, according to GlobalData. Furthermore, it’s been estimated that [...]
By
PharmaVOICE Staff
High-Science Storytelling: Cracking the Code on Meaningful Messaging
In full transparency, I am a high-science geek. I am jazzed by data, by new technologies and pathways, but most importantly, I am particularly motivated when I have the ability to work on clinically meaningful advancements that truly make a difference in patients’ lives. I am the one in the crowd who readily raises my [...]
In full transparency, I am a high-science geek. I am jazzed by data, by new technologies and pathways, but most importantly, I am particularly motivated when I have the ability to work on clinically meaningful advancements that truly make a difference in patients’ lives. I am the one in the crowd who readily raises my [...]
By
Amy Graham, Client Engagement Officer, Ogilvy Health
Facts Tell, Stories Sell
People hear facts, but feel stories, and medical storytelling today is a winning combination of both. In 2013, Novartis broke the mold in marketing with its campaign for its oral multiple sclerosis treatment Gilenya. The campaign, “Hey MS, Take This!” shows various patients sticking out their tongues with Gilenya capsules on them. Novartis reported that [...]
People hear facts, but feel stories, and medical storytelling today is a winning combination of both. In 2013, Novartis broke the mold in marketing with its campaign for its oral multiple sclerosis treatment Gilenya. The campaign, “Hey MS, Take This!” shows various patients sticking out their tongues with Gilenya capsules on them. Novartis reported that [...]
By
Robin Robinson
SHOWCASE: Virtual Health: Exploring the Potential of Virtual Health
As healthcare costs continue to spiral, the need to find effective ways to balance the demands of an aging population becomes more pressing. One approach that has the potential to make a significant difference is virtual health, which allows patients with chronic diseases to be monitored more efficiently without needing to hire more clinicians. According [...]
As healthcare costs continue to spiral, the need to find effective ways to balance the demands of an aging population becomes more pressing. One approach that has the potential to make a significant difference is virtual health, which allows patients with chronic diseases to be monitored more efficiently without needing to hire more clinicians. According [...]
By
PharmaVOICE Staff
What Do Patients Want From Virtual Trials?
How to plan for a successful patient-centric virtual trial Virtual and hybrid clinical trials, which require few or no visits to a trial site, have arrived as part of the new frontier of innovative, patient-centric research models. Through telemedicine, online patient portals, and connected devices, sponsors bring the trial directly to the patient so it’s [...]
How to plan for a successful patient-centric virtual trial Virtual and hybrid clinical trials, which require few or no visits to a trial site, have arrived as part of the new frontier of innovative, patient-centric research models. Through telemedicine, online patient portals, and connected devices, sponsors bring the trial directly to the patient so it’s [...]
By
Josh Rose, VP, IQVIA R&D Solutions Strategy and Global Head, IQVIA Virtual Trial
Wear it on Your Sleeve — How Sensors and Wearables Help Drive Richer Insights on Intervention Effects
“I didn’t sleep well last night.” It’s a phrase we’ve all heard, and unfortunately said, hundreds if not thousands of times. For some of us, the phrase instantly invokes the struggles to fall asleep, tossing and turning throughout the night. For others it means constantly waking up, gaining only an hour or two here or [...]
“I didn’t sleep well last night.” It’s a phrase we’ve all heard, and unfortunately said, hundreds if not thousands of times. For some of us, the phrase instantly invokes the struggles to fall asleep, tossing and turning throughout the night. For others it means constantly waking up, gaining only an hour or two here or [...]
By
Bill Byrom, VP Product Strategy and Innovation, Signant Health
RNAi: Advancing the Field of Biology
RNAi therapeutics, a new class of medicines, enable specific and highly effective gene silencing. RNA interference, also known as RNAi, is a breakthrough in understanding how genes are regulated in cells. RNAi has the potential to change the landscape of medicine and represents a new approach to drug discovery and development. Biopharma companies are harnessing [...]
RNAi therapeutics, a new class of medicines, enable specific and highly effective gene silencing. RNA interference, also known as RNAi, is a breakthrough in understanding how genes are regulated in cells. RNAi has the potential to change the landscape of medicine and represents a new approach to drug discovery and development. Biopharma companies are harnessing [...]
By
Denise Myshko
Unraveling Data Ownership
Amid ongoing concerns over data privacy and how patients’ data is used, who owns the data is both a crucial and complex question. Just who owns a patient’s data? It’s a question that is fraught with complications due to the sensitive nature of the information. Data has been described as the most valuable currency for [...]
Amid ongoing concerns over data privacy and how patients’ data is used, who owns the data is both a crucial and complex question. Just who owns a patient’s data? It’s a question that is fraught with complications due to the sensitive nature of the information. Data has been described as the most valuable currency for [...]
By
Kim Ribbink
Commanders & Chiefs: Biotech
Biotech and biopharma executives provide their insights on what the future holds for their sector of the industry. What should we expect to see from the biotech/biopharma industry in the coming decade? Coloma. We will see transformative-level improvement in the way we discover, develop, and commercialize drugs as a response to the changing reimbursement landscape [...]
Biotech and biopharma executives provide their insights on what the future holds for their sector of the industry. What should we expect to see from the biotech/biopharma industry in the coming decade? Coloma. We will see transformative-level improvement in the way we discover, develop, and commercialize drugs as a response to the changing reimbursement landscape [...]
By
PharmaVOICE Staff
